LONDON (Reuters) - Britain's healthcare cost watchdog has given its backing to eye drug Lucentis to treat diabetes-related problems after Swiss drugmaker Novartis offered it at a discount to the ...

SHENZHEN, CHINA, Oct. 27, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited ("CMS" or the "Group") is pleased to announce that on 27 October 2025, the Group through its subsidiary CMS ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...

The UK's cost containment agency, the National Institute for Health and Care Excellence (NICE), issued final draft guidance on 25 October 2013 recommending reimbursement for Novartis' ...

The watchdog’s investigation targets biopharma developer Samsung Bioepis, biotechs Biogen and Genentech, Novartis, and some of their units based in Italy, the Netherlands, and the U.K. The companies ...